Filing Details
Aimei Health Technology Co., Ltd. (NASDAQ:AFJK) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 13, 2026.
The Financial Services company reported Q0 revenue of .
10q filedNASDAQ:AFJK
Aimei Health Technology Co., Ltd. (AFJK) Files Quarterly Report for Q0
Aimei Health Technology Co., Ltd. (NASDAQ:AFJK) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 13, 2026.
At publication ·
What changed
Aimei Health Technology Co., Ltd. (NASDAQ:AFJK) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Aimei Health Technology Co., Ltd. (NASDAQ: AFJK) filed its quarterly 10-Q report on August 13, 2026, providing unaudited financial statements and management commentary on recent performance.
- The company's stock trades at $12.00 with a market capitalization of $197.8 million.
- The article does not disclose Q0 revenue figures, limiting visibility into the company's financial performance for the reported period.
Market Context
Aimei Health Technology Co., Ltd.'s stock currently trades at $12.00 with a market capitalization of $197.8M.
The 10-Q provides Aimei Health Technology Co., Ltd.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Aimei Health Technology Co., Ltd. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AFJK Stock Page
Frequently Asked Questions
Where can I read AFJK's SEC filings?
Browse all filings on our AFJK SEC filings page.
What types of SEC filings does Aimei Health Technology Co., Ltd. file?
Public companies like Aimei Health Technology Co., Ltd. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.